Allergy Therapeutics plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Manuel Llobet
- Full Time Employees
- 612
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Dominion Way Worthing United Kingdom BN14 8SA
- IPO Date
- Feb 3, 2010
- Website
- allergytherapeutics.com
- Similar Companies
- Business
- Allergy Therapeutics plc is a United Kingdom-based commercial biotechnology company specializing in the research, development, and commercialization of allergy immunotherapies. Its core products include aluminum-free allergen-specific immunotherapy vaccines, administered both by injection and sublingually, targeting a range of allergic disorders such as grass pollen, tree pollen, house dust mite, venom allergies, and peanut allergies. Key commercial brands include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. The company operates primarily in nine European countries through its subsidiaries and in an additional ten countries via distribution agreements. Founded in 1990 and headquartered in Worthing, United Kingdom, Allergy Therapeutics focuses on transformative immunology approaches that aim to treat the root cause of allergies rather than merely managing symptoms. Its product pipeline includes advanced-stage clinical development candidates such as Grass MATA MPL and VLP Peanut, innovative short-course vaccines designed to deliver disease-modifying effects for grass pollen and peanut allergies respectively. The company’s Grass MATA MPL vaccine has shown promising pivotal Phase III trial results, and regulatory submissions are underway in Europe. The VLP Peanut vaccine is progressing through Phase I/IIa clinical trials with the potential to revolutionize treatment for peanut allergies. Recent strategic developments include securing additional funding through expanded loan facilities with major shareholders SkyGem Acquisition Limited and Southern Fox Investments Limited, enhancing the company’s financial flexibility to advance research and development programs. Allergy Therapeutics has also maintained active engagement with regulatory bodies such as the Paul Ehrlich Institute in Germany for marketing authorization of its Grass MATA MPL vaccine. The company continues to invest heavily in its innovative pipeline and expansion, aiming to address significant unmet needs in allergy treatment markets across Europe and beyond.
Amazon and Delta announce agreement to offer improved in-flight Wifi
Grassmuno rollout to put Allergy Therapeutics on path to sustainable profitability, says broker
Grassmuno rollout to put Allergy Therapeutics on path to sustainable profitability, says broker
Allergy Therapeutics targets accelerating Grassmuno sales as peanut vaccine advances to next trial phase
Dow set to jump as easing Middle East tensions lift Wall Street futures
General Mills recovery likely multiyear, Jefferies says
Allergy Therapeutics peanut vaccine shows strong immune response in early trial
Allergy Therapeutics peanut vaccine shows strong immune response in early trial
Allergy Therapeutics reports positive data across grass pollen and peanut allergy programmes
Allergy Therapeutics reports positive data across grass pollen and peanut allergy programmes
Lululemon price target slashed on outgoing CEO’s final day
FTSE 100 Live: London stocks recover as markets await Fed chair nomination
Allergy Therapeutics announces new management hires as it looks to Hong Kong
Allergy Therapeutics announces new management hires as it looks to Hong Kong
Allergy Therapeutics update receives broker seal of approval
Allergy Therapeutics update receives broker seal of approval
Allergy Therapeutics lifts interim sales as Germany recovery gathers pace
Warner Bros Discovery rejects Paramount bid, after backer pulls out
Allergy Therapeutics German green light for Grassmuno is extremely big deal, says broker
Databricks raises $4B in funding at $134B valuation, eyes AI expansion